ENG and neoplasm: Also, in immunocompetent mice, the anti-tumor activity of anti-endoglin mAbs was higher than in immunocompromised SCID mice; the depletion of CD4+ and/or CD8+ T cells abrogated the anti-tumor efficacy of anti-endoglin mAbs, indicating that T-cell immunity may synergize with the anti-tumor activity of anti-endoglin mAbs 51, 52.